Invention Grant
- Patent Title: EML4-ALK fusion gene
-
Application No.: US14643181Application Date: 2015-03-10
-
Publication No.: US09932589B2Publication Date: 2018-04-03
- Inventor: Hiroyuki Mano , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani
- Applicant: Astellas Pharma Inc. , CureGene K.K.
- Applicant Address: JP Tokyo JP Tokyo
- Assignee: ASTELLAS PHARMA INC.,CUREGENE K.K.
- Current Assignee: ASTELLAS PHARMA INC.,CUREGENE K.K.
- Current Assignee Address: JP Tokyo JP Tokyo
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: JP2006-277718 20061011; JP2007-120670 20070501
- Main IPC: C12N15/11
- IPC: C12N15/11 ; C12N15/113 ; C07K14/47 ; C12N9/12 ; A61K31/506 ; C12Q1/48 ; C12Q1/68

Abstract:
The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
Public/Granted literature
- US20150184161A1 EML4-ALK FUSION GENE Public/Granted day:2015-07-02
Information query
IPC分类: